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1. INTRODUCTION {#mgg3754-sec-0005}
===============

Rheumatoid arthritis (RA), one of the most common systemic autoimmune disorders, is characterized by peripheral synovial joint inflammation, which ultimately leads to long‐term joint damage, loss of function, a poor quality of life, and increases mortality (Silman & Pearson, [2002](#mgg3754-bib-0028){ref-type="ref"}). A thorough comprehension of the mechanisms promoting disease persistence is required to derive targeted interventions aiming to reduce the chronic nature of RA. Although the exact causes of RA remain unknown, immunological dysregulation by inflammatory cytokines has been shown to be involved in driving the inflammation and synovial cell proliferation that characterize joint destruction in RA patients (Pawlik et al., [2016](#mgg3754-bib-0022){ref-type="ref"}; Pei et al., [2013](#mgg3754-bib-0023){ref-type="ref"}).

Advances in genotyping technology and the use of single‐nucleotide polymorphism (SNP) assays have facilitated the application of whole genome association approaches to link genetic variants with disease susceptibility (Bowes & Barton, [2008](#mgg3754-bib-0005){ref-type="ref"}; Criswell et al., [2006](#mgg3754-bib-0012){ref-type="ref"}). Heritability studies have revealed a critical role of genetic susceptibility in the progression of joint destruction in RA; the heritability is estimated as 45%--58% (Adeline et al., [2014](#mgg3754-bib-0025){ref-type="ref"}). Several SNPs were identified to be associated with RA predisposition. Large genome‐wide association studies (GWAS) have identified more than 30 loci involved in RA pathogenesis (De, [2011](#mgg3754-bib-0014){ref-type="ref"}). Genetic factors including human leukocyte antigen gene (*HLA*) (Nepom et al., [2010](#mgg3754-bib-0020){ref-type="ref"}), interleukin genes (*IL23R*, *IL6*, *IL17*, and *IL12B*) (Chabaud, Fossiez, Taupin, & Miossec, [1998](#mgg3754-bib-0009){ref-type="ref"}; Chang et al., [2010](#mgg3754-bib-0010){ref-type="ref"}), autoimmune regulator gene (*AIRE*) (José‐Raúl et al., [2013](#mgg3754-bib-0018){ref-type="ref"}), protein tyrosine phosphatase 22 (*PTPN22*) gene (Hinks et al., [2010](#mgg3754-bib-0017){ref-type="ref"}), and solute carrier family 22 member 4 (*SLC22A4*) (Newman et al., [2010](#mgg3754-bib-0021){ref-type="ref"}) have been implicated in the pathogenesis of RA.

Interleukin 2 (*IL‐2*) was initially identified as an autocrine product from activated T cells. It was found that *IL‐2* plays a crucial role in the maintenance of system homeostasis and self‐tolerance (Churlaud et al., [2014](#mgg3754-bib-0011){ref-type="ref"}; Shows et al., [1984](#mgg3754-bib-0027){ref-type="ref"}). *IL‐2* receptor alpha (*IL2RA*, OMIM: 147730) and *IL‐2* receptor beta (*IL2RB*, OMIM: 146710) genes (located in 10p15 and 22q13, respectively) were reported to be associated with the development of autoimmune diseases and inflammatory diseases, such as type 1 diabetes (TID) (Ferjani et al., [2016](#mgg3754-bib-0016){ref-type="ref"}), multiple sclerosis (Cavanillas et al., [2010](#mgg3754-bib-0007){ref-type="ref"}), inflammatory bowel disease (Bouzid et al., [2013](#mgg3754-bib-0004){ref-type="ref"}), and intermediate uveitis (Ewald, Martin, Navid, Wilfried, & Yosuf, [2015](#mgg3754-bib-0015){ref-type="ref"}). However, little studies have investigated the association between genetic variants in *IL2RA* and *IL2RB* and the risk of RA. Therefore, we performed a case--control study to analyze the associations between *IL2RA* and *IL2RB* and the risk of RA.

2. MATERIALS AND METHODS {#mgg3754-sec-0006}
========================

2.1. Subject recruitment and ethics committee statement {#mgg3754-sec-0007}
-------------------------------------------------------

In total, 499 primary arthritis patients and 507 controls were enrolled in this study; all of whom were genetically unrelated Han Chinese. All participants were recruited from the Xi\'an 630 Hospital. All primary arthritis patients were diagnosed with RA who were in clinical follow‐up of the rheumatology service for over 12 months. The control group was age‐ and gender‐matched healthy subjects without any inflammatory bone and joint disease or other diseases.

All participants were informed both in writing and verbally the procedures and purpose of the study, and they signed informed consent documents. The use of human tissue and the protocol in this study were strictly conformed to the principles expressed in the Declaration of Helsinki, and this study was carried out with approval from the ethics committee of the Xi\'an 630 Hospital. All the subsequent research analyses were carried out in accordance with the approved guidelines and regulations.

2.2. SNP selection and genotyping {#mgg3754-sec-0008}
---------------------------------

A GoldMag‐Mini Purification Kit (GoldMag Co. Ltd. Xian city, China) was used to extract genomic DNA from whole‐blood samples. DNA samples were stored at −20°C prior to analysis. At the same time, the concentrations and purity of the DNA were measured by using the NanoDrop 2000 (Thermo Fisher Scientific, Waltham, MA) at a wavelength of A260 and A280 nm.

Six tag SNPs (rs12569923, rs791588, rs12722498, rs2281089, rs3218264, and rs1573673) in *IL2RA* and *IL2RB* were selected for our study. These SNPs had minor allele frequencies (MAF) greater than 5% according to the 1000 Genomes Project (<http://www.internationalgenome.org/>). The selected SNPs were reported to be associated with inflammatory disease. The primers were designed online (<https://agenacx.com/online-tools/>). The PCR primers for each SNP are shown in Table S1. Agena MassARRAY Assay Design 4.0 software was used to design a multiplexed SNP MassEXTEND assay, and SNP genotyping was performed using the Agena MassARRAY RS1000 with manufacturer protocols. Agena Typer 4.0 software was used to perform data management and analyses.

2.3. Statistical analysis {#mgg3754-sec-0009}
-------------------------

All statistical analyses were performed using SPSS 19.0 software for Windows (SPSS, Chicago, IL). Genotyping results were performed by Agena Bioscience TYPER version software 4.0. Pearson's chi‐squared test and independent sample Student\'s *t*test were applied to assess the differences in the distribution of demographic characteristics between cases and controls. Fisher\'s exact tests for Hardy--Weinberg equilibrium (HWE) were performed by comparing the observed and expected genotype frequencies to calculate the genotype frequencies among the controls. Odds ratios (OR) and 95% confidence intervals (CI) were calculated to estimate the association between the genes (*IL2RA* and *IL2RB*) and the risk of RA using unconditional logistic regression analysis after adjusting for age and gender (Bland & Altman, [2000](#mgg3754-bib-0003){ref-type="ref"}). Four genotype model analyses (codominant, dominant, recessive, and log‐additive) were applied using PLINK software (Version 1.07) to evaluate the association between SNPs and the risk of RA. Haplotype construction and genetic association between polymorphism loci were assessed using the Haploview software package (version 4.2) and the SHEsis software (<http://analysis.bio-x.cn/myAnalysis.php>) (Barrett, Fry, Maller, & Daly, [2005](#mgg3754-bib-0002){ref-type="ref"}; YongYongSHI & LinHE, [2005](#mgg3754-bib-0026){ref-type="ref"}). All *p* values of statistical tests were two‐sided, and *p* \< 0.05 was considered as statistically significant.

3. RESULTS {#mgg3754-sec-0010}
==========

3.1. Characteristics of the participants {#mgg3754-sec-0011}
----------------------------------------

This study involved 1,006 subjects, including 499 patients (135 males and 364 females; age at diagnosis: 56.32 ± 10.02 years) and 507 healthy subjects (135 males and 372 females; age: 56.30 ± 12.68 years). The cases and controls were matched by age and sex, and there were no significant differences in the distributions of age and sex between RA patients and healthy controls (*p*﹥0.05) (Table [1](#mgg3754-tbl-0001){ref-type="table"}).

###### 

Characteristics of case and control participants

  Variables          Case            \%     Control         \%     *p*
  ------------------ --------------- ------ --------------- ------ ---------------------------------------------
  Total              499                    507                     
  Gender                                                           0.879[a](#mgg3754-note-0002){ref-type="fn"}
  Male               135             27.0   135             27.0    
  Female             364             73.0   372             73.0    
  Age (year, *SD*)   53.32 ± 10.02          56.30 ± 12.68          0.508[b](#mgg3754-note-0003){ref-type="fn"}
  ﹤54               278             56.0   246             49.0    
  ﹥54               221             44.0   261             51.0    

*p* values were calculated from two‐sided chi‐squared tests.

*p* values were calculated by Student\'s *t* tests;
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3.2. Associations between *IL2RA* and *IL2RB* SNPs and RA risk {#mgg3754-sec-0012}
--------------------------------------------------------------

Six SNPs in *IL2RA* and *IL2RB* were selected. Position, alleles, and minor allele frequency of these two SNPs were showed in Table [2](#mgg3754-tbl-0002){ref-type="table"}. All SNPs were consistent with HWE (*p*﹥0.05). Pearson's chi‐squared test was used to assess the association between SNP variants and the risk of RA. The frequency of the minor allele "G" of rs791588 was significantly lower in RA cases than in controls (32.7% vs. 39.6%), which suggested that "G" allele of rs791588 plays a protective role against RA risk (OR = 0.74, 95% CI = 0.62 -- 0.89, *p* = 0.0014).

###### 

Basic information of candidate SNPs and minor allele frequency between cases and control participants

  SNP rs\#     Chromosome   Alleles A/B   Gene(s)   MAF     *p* ~‐HWE~   OR (95% CI)   *p* ^a^             *p^b^*                                          
  ------------ ------------ ------------- --------- ------- ------------ ------------- ------------------- ----------------------------------------------- ------------------------------------------------
  rs12569923   10           C/G           *IL2RA*   0.207   0.193        1.000         1.11 (0.89--1.38)   0.347                                           0.057
  rs791588     10           G/T           *IL2RA*   0.327   0.396        0.925         0.74(0.62--0.89)    0.0014[\*](#mgg3754-note-0007){ref-type="fn"}   0.00023[\*](#mgg3754-note-0007){ref-type="fn"}
  rs12722498   10           C/T           *IL2RA*   0.110   0.111        0.649         0.99(0.75--1.31)    0.963                                           0.1605
  rs2281089    22           A/G           *IL2RB*   0.233   0.270        0.909         0.82(0.66--1.00)    0.053                                           0.0088
  rs3218264    22           C/T           *IL2RB*   0.507   0.494        0.531         1.05(0.88--1.25)    0.562                                           0.0936
  rs1573673    22           C/T           *IL2RB*   0.352   0.363        0.100         0.95(0.79--1.14)    0.594                                           0.099

Abbreviations: Alleles A/B, Minor/major alleles; CI, confidence interval; HWE, Hardy--Weinberg equilibrium; MAF, minor allele frequency; OR, odds ratio; SNP, single‐nucleotide polymorphism.

*p* ^a^ values were calculated using two‐sided chi‐squared test (the major allele of each SNP was a reference allele);

*p* ^b^ values were adjusted by Bonferroni correction.

*p* ^a^˂ 0.05 indicates statistical significance.

*p* ^b^ *˂* 0.008 indicates statistical significance.
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After adjusting for age and gender, four genotype models of *IL2RA* and *IL2RB* polymorphisms are shown in Table [3](#mgg3754-tbl-0003){ref-type="table"}. There was a significant association between one SNP and the risk of RA. The "G/G" genotype of rs791588 in *IL2RA* was associated with a decreased risk of RA as revealed by the codominant model when compared to the "T/T" genotype (OR = 0.45, 95% CI = 0.29 -- 0.69, *p* = 0.001). The "G/T‐G/G" genotype of rs791588 in *IL2RA* plays a protective role to reduce RA risk as revealed by the dominant model when compared to the "T/T" genotype (OR = 0.77, 95% CI = 0.60 --0.99, *p* = 0.046). The "G/G" genotype of rs791588 was related to a 0.48‐fold decreased risk of RA as revealed by the recessive model (OR = 0.48, 95% CI = 0.32--0.72, *p* = 0.00034) and 0.73‐fold decreased risk of RA as revealed by the log‐additive model (OR = 0.73, 95% CI = 0.61--0.88, *p* = 0.0012).

###### 

Association between candidate SNPs and the risk of RA under genotype models

  SNP            Model        Genotype   Genotype frequency   OR (95% CI)          *p*‐value                                       
  -------------- ------------ ---------- -------------------- -------------------- ----------------------------------------------- ----------------------------------------------
  *IL2RA*                                                                                                                          
  rs12569923     Codominant   G/G        327                  316                  1                                               0.314
                 C/G          154        172                  1.15 (0.88--1.50)                                                    
                 C/C          18         19                   1.07 (0.55--2.09)                                                    
  Dominant       G/G          327        316                  1                    0.320                                           
                 G/C‐C/C      172        191                  1.14 (0.88 --1.48)                                                   
  Recessive      G/G‐G/C      481        488\)                1                    0.938                                           
                 C/C          18         19                   1.03 (0.53--1.98)                                                    
  Log‐additive   ---          ---        ---                  1.11 (0.88--1.38)    0.379                                           
  rs791588       Codominant   T/T        217                  183                  1                                               0.001[\*](#mgg3754-note-0011){ref-type="fn"}
                 G/T          248        237                  0.88 (0.67--1.15)                                                    
                 G/G          42         79                   0.45 (0.29--0.69)                                                    
  Dominant       T/T          217        183                  1                    0.046[\*](#mgg3754-note-0011){ref-type="fn"}    
                 G/T‐G/G      290        316                  0.77 (0.60--0.99)                                                    
  Recessive      T/T‐G/T      465        420                  1                    0.0003[\*](#mgg3754-note-0011){ref-type="fn"}   
                 G/G          42         79                   0.48 (0.32--0.72)                                                    
  Log‐additive   ---          ---        ---                  0.73 (0.61--0.88)    0.001[\*](#mgg3754-note-0011){ref-type="fn"}    
  rs12722498     Codominant   T/T        398                  392                  1                                               0.392
                 C/T          106        96                   1.09 (0.80--1.48)                                                    
                 C/C          3          7                    0.43 (0.11--1.66)                                                    
  Dominant       T/T          398        392                  1                    0.776                                           
                 T/C‐C/C      109        103                  1.04 (0.77--1.42)                                                    
  Recessive      T/T‐T/C      504        488                  1                    0.209                                           
                 C/C          3          7                    0.42 (0.11--1.63)                                                    
  Log‐additive   ---                                          0.99 (0.75--1.32)    0.977                                           
  *IL2RB*                                                                                                                          
  rs2281089      Codominant   G/G        300                  266                  1                                               0.149
                 G/A          178        195                  0.81 (0.62--1.05)                                                    
                 A/A          29         37                   0.69 (0.41--1.15)                                                    
  Dominant       G/G          300        266                  1                    0.062                                           
                 A/G‐A/A      207        232                  0.79 (0.61--1.01)                                                    
  Recessive      G/G‐A/G      478        461                  1                    0.269                                           
                 A/A          29         37                   0.75 (0.45--1.25)                                                    
  Log‐additive   ---          ---        ---                  0.81 (0.67--1.00)    0.052                                           
  rs3218264      Codominant   T/T        116                  124                  1                                               0.781
                 C/T          268        257                  1.11 (0.82--1.51)                                                    
                 C/C          123        118                  1.11 (0.77--1.58)                                                    
  Dominant       T/T          116        124                  1                    0.482                                           
                 T/C‐C/C      391        375                  1.11 (0.83--1.48)                                                    
  Recessive      T/T‐T/C      384        381                  1                    0.846                                           
                 C/C          123        124                  1.03 (0.77--1.38)                                                    
  Log‐additive   ---          ---        ---                  1.05 (0.88--1.26)    0.581                                           
  rs1573673      Codominant   T/T        209                  193                  1                                               0.678
                 C/T          239        248                  0.89 (0.68--1.16)                                                    
                 C/C          59         57                   0.96 (0.63--1.45)                                                    
  Dominant       T/T          209        193                  1                    0.423                                           
                 T/C‐C/C      298        305                  0.90 (0.70--1.16)                                                    
  Recessive      T/T‐T/C      448        421                  1                    0.908                                           
                 C/C          59         57                   1.02 (0.69--1.51)                                                    
  Log‐additive   ---          ---        ---                  0.94 (0.78--1.15)    0.589                                           

Abbreviations: AIC, Akaike\'s information criterion; BIC, Bayesian information criterion; CI, confidence interval; OR, odds ratios, RA, rheumatoid arthritis; SNP, single‐nucleotide polymorphism.

*p* values were calculated from Wald\'s test adjusted for age and sex.

*p* ≤ 0.05 indicates statistical significance.
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3.3. Stratification analysis {#mgg3754-sec-0013}
----------------------------

As shown in Table [4](#mgg3754-tbl-0004){ref-type="table"}, we implemented a stratification analysis by gender and age to evaluate sex‐ and age‐specific associations between SNP alleles and RA risk. In the allele model, we discovered that rs791588 (*IL2RA*) and rs2281089 (*IL2RB*) significantly decreased the risk of RA in females (rs791588: OR = 0.49, 95% CI = 0.30--0.82, *p* = 0.006) and people aged under 54 (rs2281089: OR = 0.37, 95% CI = 0.21--0.68, *p* = 0.001 and OR = 0.72, 95% CI = 0.56--0.93, *p* = 0.011). In addition, rs791588 was associated with a decreased risk of RA in males (OR = 0.46, 95% CI = 0.27--0.78; OR = 0.35, 95% CI = 0.16--0.77, *p* = 0.0035; OR = 0.54, 95% CI = 0.38--0.78, *p* = 0.001) and the population over 64 years of age (OR = 0.43, 95% CI = 0.23--0.81, *p* = 0.009).

###### 

Association between sex and age stratification and RA risk in allele and genotype models

  SNP          Alleles             Male                                           Female                                         Age ≤ 54   Age﹥54                                                                                                                                              
  ------------ ------------------- ---------------------------------------------- ---------------------------------------------- ---------- ---------------------------------------------- ---------------------------------------------- ---------------------------------------------- ------- ----------------------------------------------
  *IL2RA*                                                                                                                                                                                                                                                                                        
  rs12569923   G/G                 1                                              0.353                                          1          0.739                                          1                                              0.675                                          1       0.189
  G/C          1.45 (0.86--2.47)                                                  1.05 (0.77--1.44)                                         1.08 (0.74--1.59)                                                                             1.29 (0.88--1.90)                                      
  C/C          0.89 (0.23--3.44)                                                  1.14 (0.53--2.45)                                         1.23 (0.46--3.30)                                                                             1.11 (0.44--2.76)                                      
  G            1                   0.321                                          1                                              0.616      1                                              0.983                                          1                                              0.247   
  C            1.25 (0.81--1.92)                                                  1.07 (0.13--0.83)                                         0.99 (0.73--1.36)                                                                             1.20 (0.88--1.64)                                      
  rs791588     T/T                 1                                              0.003[\*](#mgg3754-note-0015){ref-type="fn"}   1          0.006[\*](#mgg3754-note-0015){ref-type="fn"}   1                                              0.001[\*](#mgg3754-note-0015){ref-type="fn"}   1       0.009[\*](#mgg3754-note-0015){ref-type="fn"}
  G/T          0.46 (0.27--0.78)                                                  1.11 (0.81--1.51)                                         0.76 (0.52--1.11)                                                                             0.90 (0.61--1.33)                                      
  G/G          0.35 (0.16--0.77)                                                  0.49 (0.30--0.82)                                         0.37 (0.21--0.68)                                                                             0.43 (0.23--0.81)                                      
  T            1                   0.001[\*](#mgg3754-note-0015){ref-type="fn"}   1                                              0.085      1                                              0.011[\*](#mgg3754-note-0015){ref-type="fn"}   1                                              0.056   
  G            0.54 (0.38--0.78)                                                  0.83 (0.67--0.13)                                         0.72 (0.56--0.93)                                                                             0.77 (0.59--1.01)                                      
  rs12722498   T/T                 1                                              0.186                                          1          0.766                                          1                                              0.598                                          1       0.897
  T/C          1.52 (0.82--2.82)                                                  0.97 (0.67--1.39)                                         1.12 (0.73--1.72)                                                                             1.03 (0.65--1.64)                                      
  C/C          ---                                                                0.58 (0.14--2.48)                                         0.95 (0.21--4.33)                                                                             ---                                                    
  T            1                   0.495                                          1                                              0.681      1                                              0.703                                          1                                              0.673   
  C            1.21 (0.69--2.13)                                                  0.93 (0.67--1.28)                                         1.09 (0.74--1.58)                                                                             0.91 (0.60--1.39)                                      
  *IL2RB*                                                                                                                                                                                                                                                                                        
  rs2281089    G/G                 1                                              0.210                                          1          0.047[\*](#mgg3754-note-0015){ref-type="fn"}   1                                              0.004[\*](#mgg3754-note-0015){ref-type="fn"}   1       0.784
  G/A          1.06 (0.63--1.77)                                                  0.73 (0.54--0.99)                                         0.54 (0.37--0.79)                                                                             1.16 (0.79--1.71)                                      
  A/A          0.38 (0.11--1.28)                                                  0.78 (0.44--1.40)                                         0.57 (0.29--1.15)                                                                             1.09 (0.48--2.52)                                      
  G            1                   0.377                                          1                                              0.087      1                                              0.001                                          1                                              0.406   
  A            0.83 (0.55--1.25)                                                  0.81 (0.65--1.03)                                         0.62 (0.46--0.82)                                                                             1.14 (0.85--1.54)                                      
  rs3218264    T/T                 1                                              1.239                                          1          0.782                                          1                                              0.844                                          1       1.049
  T/C          1.45 (0.80--2.64)                                                  0.95 (0.67--1.35)                                         1.04 (0.68--1.59)                                                                             1.08 (0.70--1.66)                                      
  C/C          1.24 (0.60--2.59)                                                  0.94 (0.62--1.43)                                         0.89 (0.53--1.51)                                                                             0.85 (0.51--1.42)                                      
  T            1                   0.547                                          1                                                         1                                              0.876                                          1                                              0.476   
  C            1.11 (0.79--1.55)                                                  0.97 (0.79--1.19)                                         0.98 (0.77--1.25)                                                                             0.90 (0.70--1.17)                                      
  rs1573673    T/T                 1                                              0.173                                          1          0.666                                          1                                              0.134                                          1       1.148
  T/C          0.73 (0.43--1.23)                                                  0.95 (0.70--1.29)                                         0.75 (0.52--1.09)                                                                             1.01 (0.67--1.49)                                      
  C/C          1.06 (0.51--2.22)                                                  0.89 (0.54--1.48)                                         1.15 (0.63--2.07)                                                                             0.74 (0.40--1.36)                                      
  T            1                   0.791                                          1                                              0.662      1                                              0.980                                          1                                              0.351   
  C            0.95 (0.67--1.35)                                                  0.95 (0.77--1.18)                                         0.99 (0.77--1.29)                                                                             0.88 (0.68--1.14)                                      

Abbreviations: 95% CI, 95% confidence interval; OR, odds ratio; RA, rheumatoid arthritis; SNP, single‐nucleotide polymorphism.

*p^a^*‐values were calculated from Wald\'s test adjusted for age.

*p^b^*‐values were calculated from Wald\'s test adjusted for gender.

*p* \< 0.05 indicates statistical significance.
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After stratification by age and gender in the genetic model (Table [5](#mgg3754-tbl-0005){ref-type="table"}), rs791588 was significantly associated with a decreased risk of RA in males (dominant model: OR = 0.44, 95% CI = 0.27--0.72, *p* = 0.001 for the "G/T‐G/G" genotype; log‐additive model: OR = 0.55, 95% CI = 0.38--0.79, *p* = 0.001) and females (recessive model: OR = 0.47, 95% CI = 0.29--0.75, *p* = 0.002). Similarly, rs791588 plays a protective role to decrease RA risk in the population under 54 years of age (dominant model: OR = 0.66, 95% CI = 0.46--0.95, *p* = 0.024 for the "G/T‐G/G" genotype; log‐additive model: OR = 0.65, 95% CI = 0.50--0.85, *p* = 0.002) and over 54 years of age (log‐additive model: OR = 0.73, 95% CI = 0.55--0.96, *p* = 0.027).

###### 

Association between sex and age stratification and RA risk in genetic models

  Model                   Genotype   Male                Female                                         Age ≤ 54            Age﹥54                                                                                                                               
  ----------------------- ---------- ------------------- ---------------------------------------------- ------------------- ---------------------------------------------- ------------------- ---------------------------------------------- ------------------- ----------------------------------------------
  rs12569923 (*IL2RA*）                                                                                                                                                                                                                                           
  Dominant                G/G        1                   0.206                                          1                   0.684                                          1                   0.624                                          1                   0.203
                          G/C‐C/C    1.39 (0.83--2.31)                                                  1.06 (0.79--1.44)                                                  1.10 (0.76--1.59)                                                  1.27 (0.88--1.85)    
  Recessive               G/G‐G/C    1                   0.726                                          1                   0.775                                          1                   0.712                                          1                   0.987
                          C/C        0.78 (0.21--3.00)                                                  1.12 (0.52--2.38)                                                  1.20 (0.15--3.19)                                                  1.01 (0.41--2.49)    
  Log‐additive            ---        1.25 (0.80--1.94)   0.328                                          1.06 (0.82--1.37)   0.656                                          1.09 (0.78--1.51)   0.586                                          1.19 (0.87--1.64)   0.276
  rs791588 (*IL2RA*）                                                                                                                                                                                                                                             
  Dominant                T/T        1                   0.001[\*](#mgg3754-note-0019){ref-type="fn"}   1                   0.774                                          1                   0.024[\*](#mgg3754-note-0019){ref-type="fn"}   1                   0.100
                          G/T‐G/G    0.44 (0.27--0.72)                                                  0.95 (0.71--1.29)                                                  0.66 (0.46--0.95)                                                  0.78 (0.54--1.14)    
  Recessive               T/T‐G/T    1                   0.078                                          1                   0.002[\*](#mgg3754-note-0019){ref-type="fn"}   1                   0.004                                          1                   0.121
                          G/G        0.52 (0.25--1.08)                                                  0.47 (0.29--0.75)                                                  0.44 (0.25--0.76)                                                  0.45 (0.25--0.83)    
  Log‐additive            ---        0.55 (0.38--0.79)   0.001[\*](#mgg3754-note-0019){ref-type="fn"}   0.82 (0.65--1.02)   0.077                                          0.65 (0.50--0.85)   0.002[\*](#mgg3754-note-0019){ref-type="fn"}   0.73 (0.55--0.96)   0.027[\*](#mgg3754-note-0019){ref-type="fn"}
  rs12722498 (*IL2RA*）                                                                                                                                                                                                                                           
  Dominant                T/T        1                   0.292                                          1                   0.772                                          1                   0.622                                          1                   0.865
                          T/C‐C/C    1.38 (0.75--2.54)                                                  0.94 (0.67--1.35)                                                  1.11 (0.73--1.69)                                                  0.96 (0.61--1.52)    
  Recessive               T/T‐T/C    1                   0.999                                          1                   0.474                                          1                   0.924                                          1                   0.999
                          C/C        ---                                                                0.59 (0.14--2.49)                                                  0.93 (0.20--4.21)                                                  ---                  
  Log‐additive            ---        1.23 (0.69--2.17)   0.482                                          0.93 (0.67--1.29)   0.662                                          1.08 (0.74--1.59)   0.669                                          0.89 (0.57--1.38)   0.611
  rs228108 (*IL2RB*)                                                                                                                                                                                                                                              
  Domin ant               T/T        1                   0.768                                          1                   0.045                                          1                                                                  1                   0.438
                          T/C‐C/C    0.93 (0.56--1.52)                                                  0.74 (0.55--0.99)                                                  0.55 (0.38--0.78)   0.001                                          1.16 (0.80--1.67)    
  Recessive               T/T‐T/C    1                   0.109                                          1                   0.692                                          1                   0.366                                          1                   0.943
                          C/C        0.38 (0.12--1.24)                                                  0.89 (0.51--1.57)                                                  0.73 (0.38--1.43)                                                  1.03 (0.15--2.33)    
  Log‐additive            ---        0.83 (0.56--1.25)   0.388                                          0.81 (0.64--1.02)   0.078                                          0.65 (0.49--0.86)   0.003                                          1.11 (0.82--1.51)   0.502
  rs3218264(*IL2RB*)                                                                                                                                                                                                                                              
  Dominant                T/T        1                   0.250                                          1                   0.762                                          1                   0.998                                          1                   0.997
                          T/C‐C/C    1.38 (0.79--2.47)                                                  0.94 (0.68--1.32)                                                  1.00 (0.67--1.49)                                                  1.00 (0.67--1.50)    
  Recessive               T/T‐T/C    1                   0.877                                          1                   0.898                                          1                   0.540                                          1                   0.328
                          C/C        0.95 (0.53--1.73)                                                  0.97 (0.69--1.37)                                                  0.87 (0.56--1.35)                                                  0.81 (0.52--1.25)    
  Log‐additive            ---        1.13 (0.78--1.62)   0.521                                          0.97 (0.79--1.19)   0.791                                          0.95 (0.73--1.23)   0.716                                          0.93 (0.72--1.20)   0.568
  rs1573673(*IL2RB*)                                                                                                                                                                                                                                              
  Dominant                T/T        1                   0.376                                          1                   0.692                                          1                   0.267                                          1                   0.789
                          T/C‐C/C    0.80 (0.49--1.31)                                                  0.94 (0.70--1.26)                                                  0.82 (0.57--1.17)                                                  0.95 (0.65--1.39)    
  Recessive               T/T‐T/C    1                   0.491                                          1                   0.727                                          1                   0.324                                          1                   0.284
                          C/C        1.27 (0.64--2.49)                                                  0.92 (0.57--1.48)                                                  1.32 (0.76--2.31)                                                  0.74 (0.42--1.29)    
  Log‐additive            ---        0.95 (0.67--1.35)   0.789                                          0.95 (0.76--1.18)   0.642                                          0.95 (0.73--1.24)   0.718                                          0.90 (0.98--1.19)   0.462

Abbreviations: 95% CI, 95% confidence interval; OR, odds ratio; RA, rheumatoid arthritis.

*p^a^*‐values were calculated from Wald\'s test adjusted for age.

*p^b^*‐values were calculated from Wald\'s test adjusted for gender.

*p* \< 0.05 indicates statistical significance.

John Wiley & Sons, Ltd

3.4. Haplotype association {#mgg3754-sec-0014}
--------------------------

Finally, allele frequency data from all subjects was used to do the linkage disequilibrium (LD) block, and we found a strong LD in *IL2RA* between rs12569923 and rs791588 (Figure [1](#mgg3754-fig-0001){ref-type="fig"}). The results of the haplotypes and RA risk are shown in Table [6](#mgg3754-tbl-0006){ref-type="table"}. There were three haplotypes "C‐G," "G‐T," and "C‐T". However, after unconditional logistic regression analysis adjusted for age and gender, the "C‐G" and "C‐T" haplotypes significantly increased RA risk (for the "C‐G" haplotype: OR = 1.35, 95% CI = 1.12--1.64, *p* = 0.0016; for the "C‐T" haplotype: OR = 1.24, 95% CI = 1.03--1.48, *p* = 0.0016).

![Linkage disequilibrium plots containing three SNPs from *IL1RA*](MGG3-7-e00754-g001){#mgg3754-fig-0001}

###### 

Haplotype analysis results in this study

  Block     SNPs                   Haplotype                                      OR (95% CI)         *p* ^a^‐value
  --------- ---------------------- ---------------------------------------------- ------------------- -----------------------------------------------
  Block 1   rs12569923\|rs791588   CG                                             1.35 (1.12--1.64)   0.0016[\*](#mgg3754-note-0022){ref-type="fn"}
  GT        0.89 (0.71--1.12)      0.32                                                               
  CT        1.24 (1.03--1.48)      0.021[\*](#mgg3754-note-0022){ref-type="fn"}                       

Abbreviations: CI, confidence interval; OR, odds ratio; SNP, single‐nucleotide polymorphism

*p* ^a^: Adjusted by gender and age.

*p* \< 0.05 indicates statistical significance.

John Wiley & Sons, Ltd

4. DICUSSION {#mgg3754-sec-0015}
============

Persistent inflammation and progression of joint damage are the two hallmarks of RA. Several studies showed that the etiology and pathogenesis of RA were likely to comprise a multifactorial disorder resulting from environmental and genetic factors and their interaction. The present case--control study, including 499 RA patients and 507 healthy controls, was aimed to investigate the associations between six SNPs in *IL2RA* and *IL2RB* and the risk of RA in a Chinese Han population. The results showed that rs791588 (*IL2RA*) and rs2281089 (*IL2RB*) may have a protective role against RA risk.

*IL2RA* is located on the short arm of chromosome 10 (10p15‐p14), also known as CD25, which is highly expressed on CD4^+^CD25^+^regulatory T cells (Tregs) and is important for immune homeostasis and the suppression of autoimmune responses (Burchill, Jianying, Vang, & Farrar, [2007](#mgg3754-bib-0006){ref-type="ref"}). It was initially identified as a candidate gene for T1D and autoimmune disease such as multiple sclerosis. Xia, Qin, and Zhao ([2018](#mgg3754-bib-0029){ref-type="ref"}) found that the loci of *IL2RA* rs2104286 and rs12722489 are closely associated with increasing risk of multiple sclerosis in the Han and Hui nationalities. Abdelrahman et al. ([2016](#mgg3754-bib-0001){ref-type="ref"}) indicated that *IL2RA* was found to be associated with several autoimmune diseases including T1D, and *IL2RA* was more likely to develop T1D (OR = 2.8, *p* = 0.03) in Egyptian children. However, one study showed no significant relationship was observed between the polymorphism of *IL2RA* and T1D in children of northwest of Iran (Ranjouri et al., [2016](#mgg3754-bib-0024){ref-type="ref"}). Dai et al. ([2013](#mgg3754-bib-0013){ref-type="ref"}) revealed that *IL2RA* was associated with an increased risk of neuromyelitis optica in southern Han Chinese. Another study reported that the variants of *IL2RA* showed a protective role against the intermediate uveitis (Ewald et al., [2015](#mgg3754-bib-0015){ref-type="ref"}). Based on genetic and serologic study, Knevel et al. ([2013](#mgg3754-bib-0019){ref-type="ref"}) found that inherited altered genetic constitution at *IL2RA* may predispose to a less destructive course of RA. The result of our study showed *IL2RA* (rs791588) was associated with decreasing risk of RA in the Chinese Han population. The difference in results may vary depending on the sample size, ethnicity, test method, and so on.

*IL2RB* encodes the subunit of interleukin‐2 receptor (*IL2R*) and is primarily expressed in the hematopoietic system, where it is involved in the activation of T‐ and NK cell subsets. There is little research on *IL2RB* genes polymorphisms and genetic susceptibility to disease. One study indicated that *IL2RB* polymorphisms do not seem to play a significant role in the non‐anterior uveitis genetic predisposition (Cénit et al., [2013](#mgg3754-bib-0008){ref-type="ref"}). Another study found that *IL2RB* polymorphisms were not associated with inflammatory bowel disease risk as well. However, Adeline et al. ([2014](#mgg3754-bib-0025){ref-type="ref"}) revealed that a haplotype constructed with two SNPs (rs743777 and rs3218253) located in *IL2RB* was associated with erosive status in early RA. The present study found the polymorphism of *IL2RB* (rs2281089) significantly decreased the risk of RA. The relationship of *IL2RB* gene polymorphisms and other diseases should be investigated in future studies.

Our study aimed to report the association between the polymorphisms of *IL2RA* and *IL2RB* and the risk of RA in the Chinese Han population, which may provide new data to facilitate earlier diagnosis and promote early prevention, and shed light on the new candidate genes and new ideas for the study of subsequent occurrence mechanism of RA. However, some potential limitations of our current study should be considered when decipher the results. This study is only a preliminary basic research; further functional studies and larger population‐based prospective studies are required to understand the genetic factors underlying RA in the subsequent research.

5. CONCLUSION {#mgg3754-sec-0016}
=============

Our results indicate that rs791588 (*IL2RA*) and rs2281089 (*IL2RB*) polymorphisms are associated with RA in a Chinese Han population. These SNPs may serve as prognostic biomarkers for RA in the Chinese Han population.
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